Breaking Barriers in HER2+ Cancers.

[1]  Y. Bang,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.

[2]  A. Grothey,et al.  A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. , 2020 .

[3]  B. Taylor,et al.  First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[4]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[5]  A. Bass,et al.  A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. , 2019, Cancer research.

[6]  H. Iwata,et al.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. , 2019, The Lancet. Oncology.

[7]  G. Pruneri,et al.  The landscape of d16HER2 splice variant expression across HER2-positive cancers , 2019, Scientific Reports.

[8]  B. Taylor,et al.  EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. , 2018, Cancer discovery.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  A. Bardelli,et al.  Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. , 2018, Cancer cell.

[11]  David R. Jones,et al.  Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. , 2018, Cancer discovery.

[12]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.